Diabetes

Global Domiciliary Insurance Market Report to 2031 - Featuring Cigna, Allianz, AXA and Edelweiss Health Insurance Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 14, 2022

The domiciliary insurance market consists of sales of domiciliary insurance services by entities that are engaged in direct underwriting insurance policies for home-based treatment done for a disease, illness, or injury.

Key Points: 
  • The domiciliary insurance market consists of sales of domiciliary insurance services by entities that are engaged in direct underwriting insurance policies for home-based treatment done for a disease, illness, or injury.
  • The main types of domiciliary insurance are diseases insurance, medical insurance, income protection insurance, and other insurance.
  • Diseases insurance refers to the domiciliary insurance that is issued to an individual that covers the policy for critical diseases.
  • This has allowed the companies in the domiciliary insurance market to cater the domiciliary insurance services along with the normal health insurance policy specific to COVID.

Preclinical Data Demonstrate Potential of Creative Bio-Peptides’ Multi-Chemokine Receptor Antagonist RAP-103 to Provide Opioid Sparing Post-Surgical Pain Relief and Treatment for Chronic Pain

Retrieved on: 
Thursday, July 14, 2022

These data were published online on July 9 ahead of print in the peer-reviewed scientific journal Life Sciences.

Key Points: 
  • These data were published online on July 9 ahead of print in the peer-reviewed scientific journal Life Sciences.
  • RAP-103 balances the inflammatory response by blocking several small peptide hormones of the innate immune system called chemokines, resulting in less pain, neuronal regeneration, and reduced opioid use.
  • The results identify chemokine receptor antagonist RAP-103 as a potential treatment to reduce post-surgical acute pain in the presence of an opioid and as a non-opioid treatment for chronic pain conditions, including diabetic peripheral neuropathy (DPN) and persistent post-surgical pain (PPSP).
  • Forward looking statement: Creative Bio-Peptides is currently completing IND-enabling studies and is currently raising funding to begin clinical trials in mid-2023.

LG Chem Announces First Subject Enrolled in Phase 1 Clinical Trial of NASH New Drug

Retrieved on: 
Thursday, July 14, 2022

LG Chem recently announced the enrollment of first subject in Phase 1 clinical trial of LG203003, LG Chems second NASH (non-alcoholic steatohepatitis) drug in development.

Key Points: 
  • LG Chem recently announced the enrollment of first subject in Phase 1 clinical trial of LG203003, LG Chems second NASH (non-alcoholic steatohepatitis) drug in development.
  • First subject was dosed on July 6, 2022, and the trial will evaluate the safety, tolerability, as well as the pharmacokinetics (PK) and pharmacodynamics (PD) of LG203003.
  • NASH is the major cause of liver cirrhosis, liver transplantation, and HCC (hepatocellular carcinoma) in western countries.
  • LG Chem Life Sciences is a business division within LG Chem, engaged in development, manufacturing, and global commercialization of pharmaceutical products.

GI Dynamics Announces the Presentation of Updated Data Sets at the 2022 Meeting of the American Diabetes Association

Retrieved on: 
Thursday, July 14, 2022

of City Hospital, Birmingham, U.K. at the 82nd Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans on June 6, 2022.

Key Points: 
  • of City Hospital, Birmingham, U.K. at the 82nd Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans on June 6, 2022.
  • Both studies demonstrate the safety and efficacy profile that EndoBarrier provides patients diagnosed with type 2 diabetes and/or obesity.
  • The Worldwide EndoBarrier Registry continues to support a positive benefit:risk profile for patients with type 2 diabetes and/or obesity treated with EndoBarrier.
  • Many benefits are seen in patients including considerable improvements in weight, HbA1c, systolic blood pressure and cholesterol as shown below:

Nefertiti Greene Joins Mars Petcare to Run New Science & Diagnostics Division

Retrieved on: 
Thursday, July 14, 2022

Greene will head new division within Mars Petcare, Science & Diagnostics

Key Points: 
  • Greene will head new division within Mars Petcare, Science & Diagnostics
    BRUSSELS, July 14, 2022 /PRNewswire/ -- Today, Mars Petcare , the leading pet health, services, and nutrition company, has named Nefertiti Greene asPresident of the business's new division, Science & Diagnostics.
  • Reporting to Loic Moutault, President of Mars Petcare, and as a member of the Petcare leadership team, Greene will oversee the growing diagnostics business and lead science across Mars Petcare, including the Waltham Petcare Science Institute .
  • The new Mars Petcare Science & Diagnostics division builds on the business' heritage in science and leadership in predictive diagnostics.
  • Greene said:"I am excited to join the Mars Petcare leadership team and look forward to using my experience in the healthcare industry to help build on the successes in diagnostics and science at Mars Petcare.

Nefertiti Greene Joins Mars Petcare to Run New Science & Diagnostics Division

Retrieved on: 
Thursday, July 14, 2022

Greene will head new division within Mars Petcare, Science & Diagnostics

Key Points: 
  • Greene will head new division within Mars Petcare, Science & Diagnostics
    BRUSSELS, July 14, 2022 /PRNewswire/ -- Today, Mars Petcare , the leading pet health, services, and nutrition company, has named Nefertiti Greene asPresident of the business's new division, Science & Diagnostics.
  • Reporting to Loic Moutault, President of Mars Petcare, and as a member of the Petcare leadership team, Greene will oversee the growing diagnostics business and lead science across Mars Petcare, including the Waltham Petcare Science Institute .
  • The new Mars Petcare Science & Diagnostics division builds on the business' heritage in science and leadership in predictive diagnostics.
  • Greene said:"I am excited to join the Mars Petcare leadership team and look forward to using my experience in the healthcare industry to help build on the successes in diagnostics and science at Mars Petcare.

Supersapiens Welcomes Multiple IRONMAN 70.3 Champion Emma Pallant-Browne as Ambassador

Retrieved on: 
Thursday, July 14, 2022

Originally from Surrey, Pallant-Browne has proven herself to be one of the top female athletes in the triathlon's middle distance. Throughout her career, she has earned 13 podium finishes and nine wins. She's started 2022 with a splash -- taking wins at Ironman 70.3 LUX, Challenge Riccione, and IRONMAN 70.3 Elsinore, which served as the European Championships. She has also enjoyed a taste of success over the full distance with a podium at IRONMAN Austria (2018) - her best result at that distance to date.

Key Points: 
  • ATLANTA, July 14, 2022 /PRNewswire/ -- Supersapiens, the world's first energy management system designed for athletes to unlock higher performance and recovery, welcomes Emma Pallant-Browne as an ambassador.
  • Supersapiens, powered by the Abbott Libre Sense Glucose Sport Biosensor, plans to work with Emma to bring the technology and training knowledge to the triathlon community.
  • She has also enjoyed a taste of success over the full distance with a podium at IRONMAN Austria (2018) - her best result at that distance to date.
  • Excited to join Supersapiens, Pallant-Browne says, "From experience I have seen how bad things can go when you don't fuel well.

Global Enteral Nutrition Market (2022 to 2027) - Players Include Byram Healthcare Centers, CONMED, Cardinal Health and Danone - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 14, 2022

Market dynamics are forces that impact the prices and behaviors of the Global Enteral Nutrition Market stakeholders.

Key Points: 
  • Market dynamics are forces that impact the prices and behaviors of the Global Enteral Nutrition Market stakeholders.
  • The report presents a detailed Ansoff matrix analysis for the Global Enteral Nutrition Market.
  • The report analyses the Global Enteral Nutrition Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The Global Enteral Nutrition Market is segmented based on Product, Application, End User, Distribution Channel, and Geography.

$9.1 Billion Worldwide Influenza Vaccine Industry to 2027 - Featuring Abbott Laboratories, AstraZeneca, CSL and Daiichi Sankyo Company Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 14, 2022

Influenza vaccines, also known as flu shots, provide protection against various types of influenza viruses.

Key Points: 
  • Influenza vaccines, also known as flu shots, provide protection against various types of influenza viruses.
  • They are available in several options, including inactivated influenza vaccine [IIV], recombinant influenza vaccine [RIV], and live attenuated influenza vaccine (LAIV).
  • Presently, governments of numerous countries have mandated immunization against influenza among children between six months and five years of age.
  • What is the structure of the global influenza vaccine market and who are the key players?

BUSINESS UPDATE

Retrieved on: 
Thursday, July 14, 2022

Arecor is pleased to report progress in line with expectations, as the Group continues to drive forward a commercially focused business model, advancing its best-in-class proprietary pipeline and expanding its partnered portfolio.

Key Points: 
  • Arecor is pleased to report progress in line with expectations, as the Group continues to drive forward a commercially focused business model, advancing its best-in-class proprietary pipeline and expanding its partnered portfolio.
  • The pipeline for future revenue generating partnered collaborations is strong with further deals anticipated in H2 and beyond.
  • Here, Arecor is applying the ArestatTM technology to develop improved, stable, high concentration liquid formulations of the partner companys proprietary products.
  • This progress gives us confidence in Arecors science and business model, which underpins our vision to transform patient care and our ambition to build a large self-sustaining biopharmaceutical company.